ALFA Finder| Revenue growth | 23% YoY revenue growth to ₹6,813 crore in FY26. |
|---|---|
| Margins | EBITDA margins expanded 6.7% points to 26.8% due to mix. |
| Demand visibility | Strong visibility for CDMO; servicing 1/3rd of global HIV population. |
| Management confidence | Balanced confidence; shifting focus to high-growth CDMO and new modalities. |
Growth
FY26 revenue reached ₹6,813 crore, driven by a 38% surge in small molecule CDMO and affordable medicines growth.
Outlook
Guided 50% CDMO revenue share by 2030; ₹3,000 crore capex planned over the next two years.
Risks
Geopolitical disruptions affecting raw material logistics; high capex intensity may pressure near-term free cash flow.
Earnings Call filed with BSE, NSE: LAURUSLABS. Summary written with AI assistance from the document.
Laurus Labs Ltd: key numbers
- Share price
- ₹2,429.00
- Market cap
- ₹1,31,242 Cr
- Revenue (annual)
- ₹6,813 Cr
- Net profit (annual)
- ₹888.8 Cr
- P/E (TTM)
- 98.0×Sector 43.8×
- Promoter holding
- 27.47%+0.00% QoQ
- FII holding
- 30.84%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Laurus Labs Ltd
All →Laurus Labs Earnings Call Transcript: Key Takeaways
Laurus Labs delivered record revenue driven by CDMO strength and API growth. While margins improved through operating leverage, high capex continues to constrain free cash flow.
Laurus Labs Results Update
Laurus Labs reported H1 FY27 revenue of ₹4,233 Cr and EBITDA of ₹1,406 Cr. The company acquired Galenvs Sciences and SI&C Resins to expand CDMO capabilities.
- SPPS peptide synthesis capacity
- 16000 L
Laurus Labs Investor Presentation: Key Takeaways
Q2/H1 FY27: H1 revenue ₹4,233 Cr (+31%), EBITDA ₹1,406 Cr (33.2% margin), PAT ₹809 Cr (+126%). CDMO-led growth; ₹3,000 Cr+ capex planned FY27-28.
Laurus Labs Dividend
Laurus Labs approved a Re. 1.00 per share interim dividend for FY 2026-27. Record date is November 6, 2026; payment on or after November 19, 2026.
Laurus Labs Management Change
Laurus Labs appointed Mr. Kundan Kumar Jha as Joint Company Secretary effective November 1, 2026, following Board approval. The KMP appointment advances the company's succession planning process.
Laurus Labs Acquisition Worth ₹32.5 Cr
Laurus Labs approved acquiring 52% of SI & C Resins for Rs. 32.50 Crore. The acquisition makes SI&C a subsidiary for peptide resin manufacturing.
- Value
- ₹32.50 Cr